ImmunoCellular +13.2%, wins orphan drug status for ICT-107 in the EU

|About: ImmunoCellular Therapeutics... (IMUC)|By:, SA News Editor

ImmunoCellular Therapeutics (IMUC +13.2%) says it has been granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma.

Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives.

IMUC already had received orphan designation for ICT-107 in glioblastoma in the U.S.